Who Are We?

ForDoz Pharma is an innovative commercial-stage pharmaceutical company based in East Windsor, NJ. We focus on developing, manufacturing, and commercializing innovative complex injectables for patients with severe and chronic diseases.

Founded in 2014 to help address significant unmet medical needs, the company aims to accelerate the development of innovative complex injectable medicines and therapies. ForDoz’s experienced team has successfully developed proprietary particle-based drug delivery technology platforms, generating a broad pipeline of generic as well as 505(b)(2) innovative complex injectable products.

In 2018, we successfully built our first state-of-the-art cGMP sterile manufacturing facility dedicated to the commercial manufacturing of complex injectable products. In July 2024, we received FDA approval for our first product, Doxorubicin Hydrochloride liposomal injection, and we launched the product in US market in August 2024. ForDoz has supplemented its pipeline with 505(b)(2) patented innovative long-acting injectable (LAI) products. At the same time, we offer CDMO services to other companies to develop and manufacture their pipeline complex injectable products.

ForDoz Pharma is a fully integrated pharmaceutical company with end-to-end capabilities. ForDoz has an internal R&D team to advance innovative products, quality and production teams experienced in cGMP sterile manufacturing and quality control, an experienced regulatory affairs team, and highly specialized commercial marketing and sales partners worldwide. This integrated approach provides sustainable competitive advantages for ForDoz and its partners.